Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Growth Opportunities are Expected to Drive the Aurora Kinase B Market’s CAGR Through 2034?

The market size for aurora kinase b has experienced swift expansion in the last few years. Expected to increase from $1.14 billion in 2024 to $1.27 billion in 2025, this market will grow at a compound annual growth rate (CAGR) of 12.1%. Factors contributing to this growth during the historical period include an increased demand for specific cancer treatments, a global rise in cancer cases, escalated investments in precision medicine, and an increase in both the number of clinical trials, and governmental funding for cancer research.

In the coming years, the market size of aurora kinase b is predicted to experience swift expansion, with an estimated worth of $1.99 billion in 2029 and a compound annual growth rate (CAGR) of 11.8%. This surge within the forecasted period is anticipated due to an increase in funding for cutting-edge cancer treatments, the escalating occurrence of drug-resistant cancers, augmented research and development efforts, a growing demand for combination therapies, and a rising prevalence of firm tumors. Foreseen trends for the period include progress in technology, precision-oriented medication, innovative treatment methodologies, data analytics, and unique therapies.

What Industry-Specific Factors Are Fueling the Growth of the Aurora Kinase B Market?

The upward trend in cancer cases is predicted to fuel the expansion of the aurora kinase B market. Cancer is a collection of diseases defined by uncontrolled proliferation and dispersion of abnormal cells, which can intrude on nearby tissues and spread to other body parts. The increase in cancer cases can be attributed to factors like aging population, shifts in lifestyle, environmental exposure, and advancements in detection and diagnosis. Aurora kinase B has a vital function in mitosis, and its overproduction is associated with chromosomal instability and the advancement of cancer. Due to its role in the division of tumor cells, it is regularly targeted in cancer treatments. The World Health Organization, a Swiss intergovernmental organization, reported in February 2024, that approximately 20 million new cancer cases and 9.7 million deaths occurred in 2022. By 2050, it is anticipated that new cancer instances will surpass 35 million, marking a 77% rise from 2022. Hence, the increasing prevalence of cancer is reinforcing the growth of the aurora kinase B market.

Request Your Free Aurora Kinase B Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

What Are the Leading Industry Players Dominating the Aurora Kinase B Market?

Major companies operating in the aurora kinase B market are:

• Pfizer Inc._x000D_

• Johnson & Johnson_x000D_

• Roche Holding AG_x000D_

• Merck & Co. Inc._x000D_

• AbbVie Inc._x000D_

What Are the Latest Trends Leading to Disruption in the Aurora Kinase B Market?

Key players in the Aurora kinase B industry are focusing their efforts on the creation of advanced products, notably aurora kinase inhibitors, which are specifically devised to interfere with crucial cell division processes. These inhibitor drugs are engineered to impede the tasks of Aurora kinases, pivotal for cell division, hence interrupting the multiplication of cancer cells and potentially diminishing tumor growth. For example, Ellipses Pharma, a biotech firm based in the UK, received approval from the U.S. Food and Drug Administration (FDA) in June 2023 for its dual FLT-3 and Aurora kinase inhibitor, EP0042. This drug is under development to treat acute myeloid leukemia (AML) by inhibiting both FLT3 and Aurora kinase, specifically devised for patients who have grown resistant to FLT3 inhibitors. Studies show that combined inhibition of FLT3 and Aurora kinase can beat the acquired resistance to targeted FLT3 inhibition, in both lab settings and living organisms.

Get Instant Access to the Global Aurora Kinase B Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

What Are the Strategic Segments Comprising the Aurora Kinase B Market and Their Growth Contributions?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Which Regions Are Significant to the Growth of the Aurora Kinase B Market?

North America was the largest region in the aurora kinase B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Can We Define the Aurora Kinase B Market and Its Key Components?

Aurora kinase B is a protein enzyme that plays a critical role in cell division, particularly during mitosis. It is involved in regulating chromosome alignment, segregation, and the proper distribution of genetic material to daughter cells. Aurora kinase B is essential for maintaining genomic stability, and its dysregulation is often associated with various cancers.

Browse Through More Similar Reports By The Business Research Company:

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: